Friedrich-Schiller-University Jena
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Guntinas-Lichius, Orlando
NANORAY-312, NCT04892173: NBTXR3 With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Canada, Japan, US, RoW
NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy
Nanobiotix
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
07/24
01/26
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn
2
130
Europe, US, RoW
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Replimune Inc., Bristol-Myers Squibb
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
03/26
06/26
Wittekindt, Claus
ANCHOR-1, NCT05274750: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Completed
3
276
Europe, Canada, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline
Nasal Polyps
07/24
08/24

Download Options